mutations, in whom rituximab appears to acquire little extra value.fifty nine Other genomic subgroups, such as sufferers with BIRC3translocations or amplifications along with the genomic alterations already existing in the original CLL, but lack the popular mutations noticed in Key DLBCL indicating which they may possibly correspond to another biol